Author of

• 17493

  +

  P2.02 - Poster Session with Presenters Present (ID 462)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Locally Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17552

    +

    P2.02-059 - New Treatment Strategy in Inoperabl Locoregionally Advanced NSCLC: C Arm Cone Beam CT-GuıDed Selective Intraarterial Chemotherapy (ID 5107)

    14:30 - 14:30  |  Author(s): S. Yılmaz
    • Abstract

    Background:
    The optimal treatment of patients with stage III Non-small cell lung cancer (NSCLC) has not been clearly defined. Although there are many treatment options, none of them have a high probility of cure. A multidisciplinary approch is important for this patients. Aim of this study was to determine efficacy and toxicity of C arm Cone Beam CT (CACBCT) guided selective intraarterial chemotherapy (IACH) for patients who had inoperabl locoregionally advanced NSCLC.
    
    Methods:
    Patients: Our study included 27 Non-small cell lung cancer (NSCLC) patients who were treated with IACT in the Department of Medical Oncology at Antalya Memorial Cancer Center between September 2012 and March 2016. Only patients with inoperabl NSCLC who had a life expectancy longer than 3 months were included in study. They were previously untreated patients. Chemoembolization: The treatment was performed using intra-arterial platin based combination chemotherapy every 21 days for 2-4 cycles by CACBCT. In all patients, via the femoral artery, CACBCT angiographies were taken and the feeding arteries of the tumors were identified. These arteries were then selectively catheterized and cisplatin+docetaxel combination was infused. If patients had good response the treatment after first two cycles, they underwent the surgery. Other patients had continued chemoradiotherapy.
    
    Results:
    Two patients were female and twenty-five patients were male. Thirteen of patients had non-squamous, fourteen patients had squamous cell lung cancer. The average age of the patients was 58.9 years (range 46-78 years). The post-treatment radiological response evaluation of the patients is as follows: 3 patients(11,1%) had stable disease, 19 patients(70,3 %) had a partial response, 3 patients(11.1%) had a complete response and progressive disease was observed in 2 patients (7.4 %). Objective Response Rate was 90.5%. Surgical resection was performed thirteen(%48.1) of the patients. A pathological complete response was achieved in 5 patients who were operated on after receiving IACH. Other patients: two patients were stage 1A; two were stage 2A while four patients were stage 3A. Median follow-up time 21.2 months and this time OS was 63%. In terms of toxicity grade 1-2 anemia in five patients, grade 3 neutropenia in two patients, grade 2 thrombocytopenia in one patient was detected. However, no other complications are observed in any other patients.
    
    Conclusion:
    This study has shown that in our experience IACH is an effective and less toxic in inoperabl locoregionally advanced NSCLC regardless of the histology. This treatment strategy is combinations of surgery or chemoradiotheray hopfull for this patients.